STOCK TITAN

Becton, Dickinson and Co. (BDX) Stock News

BDX NYSE

Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.

BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.

Rhea-AI Summary

BD (BDX) marked the 85th anniversary of its medical device manufacturing site in Glens Falls, New York, the longest-running facility in its network. The site opened in 1941 with 35 employees and now has about 550 associates. It produces approximately 6.5 million medical devices annually and has 825 distinct product items across 20 product lines, serving areas such as vascular intervention, cardiac care and urology.

As part of the anniversary celebration, BD donated $10,000 to Open Door Mission, which provides food assistance and shelter in the region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
Rhea-AI Summary

BD (BDX) was named to TIME's 2027 list of America's Top Manufacturers following an independent evaluation of U.S. manufacturers.

BD was among 250 companies selected from thousands of eligible manufacturers. TIME and Statista developed the ranking, which assessed financial performance, capacity to innovate and employment. It was BD's second recognition from TIME in 2026, following its inclusion on the 2026 list of America's Best Companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
Rhea-AI Summary

BD (NYSE: BDX) will host an Investor Day for institutional investors and financial analysts on December 10, 2026, in New York. The program begins at 8:30 a.m. ET. CEO Tom Polen, CFO Vitor Roque and other leaders will discuss business strategy, capital deployment priorities and the long-term outlook, followed by questions and answers. A live webcast and subsequent replay will be available on the investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
conferences
Rhea-AI Summary

BD (NYSE: BDX) reported fourth-quarter fiscal 2026 revenue of $5.274 billion, with growth across all four continuing business segments. Revenue rose 5.4% year over year; GAAP diluted earnings per share increased 110.0% to $2.52, while adjusted EPS rose 27.3% to $4.15.

For the year ended September 30, revenue increased 4.9% to $19.5 billion. GAAP and adjusted diluted EPS were $5.06 and $12.70, respectively. Continuing operating cash flow rose 30.0% to $3.6 billion, and free cash flow increased 42.5% to $2.9 billion.

BD expects fiscal 2027 revenue growth in the low single digits and adjusted diluted EPS of $13.10–$13.30. It plans $19 billion of U.S. investment over several years under a government partnership. Results exclude the former Biosciences and Diagnostic Solutions business, whose spin-off and combination with Waters closed February 9, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
-
Rhea-AI Summary

BD (NYSE: BDX) raised its quarterly dividend to $1.06 per common share and authorized additional share repurchases.

The dividend is up 1.0% from the previous quarter and is payable December 31, 2026, to holders of record December 10, 2026. The indicated annual rate is $4.24 per share. The board authorized repurchases of up to 10 million additional shares, beyond shares remaining under its previous 2026 authorization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
buybacks dividends
-
Rhea-AI Summary

BD (NYSE: BDX) appointed Bridget Bagnato worldwide president of its Peripheral Intervention business unit, effective November 16, 2026.

Based at the unit's headquarters in Tempe, Arizona, she will oversee its global strategic, operational and commercial performance and report to Peter Menziuso, executive vice president and president of the Interventional segment. Bagnato currently leads BD's Specimen Management business unit and has held leadership roles across the company during more than 27 years at BD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
Rhea-AI Summary

BD (BDX) announced the U.S. commercial launch of its Liverty TIPS Stent Graft for patients with complications of portal hypertension. TIPS is a minimally invasive procedure that creates a new blood-flow pathway in the liver to relieve pressure.

BD says the system is designed to help physicians tailor treatment to individual anatomy and clinical needs. The launch is supported by six-month interim results from the prospective, multicenter ARCH study involving 177 patients; no numerical clinical outcomes were provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary

BD (BDX) will host an audio webcast on November 5, 2026, to discuss its fourth-quarter and full-year fiscal 2026 financial results.

The webcast begins at 8 a.m. ET and will include an operations and strategy update. The fiscal year ended September 30, 2026. BD will release financial information and presentation materials before the call on its investor relations website, where a replay will also be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
earnings date
-
Rhea-AI Summary

BD (NYSE: BDX) joined the Global Surgery Foundation and Business Council for International Understanding to convene a maternal-safety panel on September 24.

Held at the Japan Society alongside the 81st United Nations General Assembly, the discussion explored continuous noninvasive blood pressure monitoring and other measures of blood circulation to help clinicians recognize childbirth complications earlier. Participants called for broader adoption of evidence-based maternal care and improved monitoring standards. The discussion addressed progress toward the UN goal of fewer than 70 maternal deaths per 100,000 live births by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
Rhea-AI Summary

BD (NYSE: BDX) announced nine-month AGILITY trial results showing its Revello Vascular Covered Stent met the primary endpoint in iliac artery disease.

The cohort enrolled 120 patients at 28 sites. The combined safety and effectiveness endpoint had a 2.8% failure rate, significantly below the prespecified 19% performance goal. Primary patency, meaning treated arteries remained open, was 97.2%; freedom from clinically driven repeat treatment of the target lesion was 98.3%. There were no device- or procedure-related deaths, target limb major amputations or unanticipated serious adverse device effects. Mean Rutherford disease-severity category improved from 3.0 to 0.3, and the mean walking impairment questionnaire score rose 31.7 points from baseline.

Follow-up continues through 36 months. Enrollment in a separate leg-artery cohort finished in August. Revello is CE marked but remains limited to investigational use in the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none

FAQ

What is the current stock price of Becton, Dickinson (BDX)?

Becton, Dickinson (BDX) last closed at $212.78.

What is the market cap of Becton, Dickinson (BDX)?

The market cap of Becton, Dickinson (BDX) is approximately $58.0B.